Bolt Projects Holdings, Inc. (BSLKW)

Bolt Projects makes ingredients for shampoo, conditioner, and cosmetics—but not the way the industry has for decades. The company grows them in fermentation tanks. The flagship product is b-silk, a biodegradable polypeptide that mimics the properties of real silk protein but is made from engineered microbes rather than extracted from silkworm cocoons. It sounds futuristic, but the product is already on shelves: hundreds of beauty brands have incorporated b-silk into their haircare and skincare lines since 2019.

The company was founded in 2009 and was originally known as Bolt Threads. It spent over a decade perfecting fermentation chemistry and securing partnerships with major beauty and fashion brands. In 2024, Bolt Projects went public through a merger with a blank-check company (Golden Arrow Merger Corp) and began trading on the Nasdaq under the ticker BSLK, with warrants trading as BSLKW. The IPO raised capital but also exposed the company to the scrutiny of public markets, which have been skeptical. The stock has struggled, raising questions about whether the market believes the company can scale manufacturing and turn its innovations into sustained profitability.

What b-silk is and why beauty brands care

Silk proteins are used in cosmetics because they coat hair, provide shine, and reduce frizz. Conventional silk is expensive to extract—it requires boiling silkworm pupae and unwinding cocoons. The alternative was synthetic polymers, which perform adequately but feel inferior and raise sustainability concerns. B-silk is a middle path: it is a fermentation-derived polypeptide that performs like real silk but is fully vegan, biodegradable, and produced in fermentation tanks at a cost that competes with synthetics.

For beauty brands, the appeal is straightforward. Consumers are willing to pay premiums for products labeled “vegan” and “sustainable,” and b-silk delivers on both claims. It also performs: independent testing has shown that b-silk-formulated products offer performance comparable to silkworm-derived silk. Because Bolt Projects does not harvest, brand, and sell directly to consumers, the company’s business model is purely ingredient supply. Brands like Stella McCartney, Adidas, and mainstream beauty companies have licensed b-silk for use in their products. Bolt Projects earns revenue per kilogram of ingredient sold, with gross margins that depend on fermentation scale and input costs.

The fermentation challenge

Making ingredients via fermentation is not new. Companies have been using yeast and bacteria to produce everything from antibiotics to insulin for decades. But fermentation is capital-intensive: you need bioreactors, sterile manufacturing facilities, downstream purification equipment, quality control systems, and regulatory compliance. Scale matters enormously. At small volumes, fermentation is expensive. At large volumes, if you can achieve consistent quality, it can be cost-competitive with conventional manufacturing.

Bolt Projects has built fermentation capacity, but the question is whether that capacity is sufficient to meet demand. If brand demand for b-silk outpaces the company’s ability to supply it, the company must choose between rationing supply (limiting growth) or investing heavily in new manufacturing (draining cash). If demand is weaker than anticipated, the company is left with excess capacity and sunk capital costs. That tension is central to the biotech manufacturing play.

The company also produces MYLO, a mycelium-based leather alternative, and MICROSILK, a silk fiber for textiles. These represent the breadth of the fermentation platform. But they also represent diluted focus—the company is attempting to serve multiple end markets (beauty, fashion, textiles) rather than dominating one. That is a strategic choice that creates risk: it allows the company to capture multiple revenue streams but forces it to invest in manufacturing capacity across different platforms and navigate different customer relationships and supply chains.

How the company funds itself

Bolt Projects has two sources of capital: the cash it raises through public markets (the IPO and any subsequent offerings) and the cash it generates from selling b-silk and other products to beauty and fashion brands. The company is not yet profitable on an operating basis, meaning the cash from ingredient sales does not yet cover the overhead of running the company plus the investment in manufacturing. The company is therefore dependent on the capital it raised in the IPO to fund the cash burn while it scales.

That dependency creates pressure. If the company can demonstrate that its ingredient sales are growing and that gross margins are expanding toward levels that would eventually cover overhead, it can raise additional capital or earn it through improved operations. If sales growth slows or margins compress (because of manufacturing inefficiencies or price competition), the company’s path to self-sufficiency narrows, and it may need to raise capital at dilutive terms or consider strategic options like acquisition or partnerships.

The company’s capital strategy reflects its stage: it is betting that fermentation-derived beauty and textile ingredients represent a genuine market opportunity, that customers will prefer its products, and that scale will create competitive advantage. Those are reasonable bets, but they are still bets. The company has not yet proven that it can manufacture at scale without significant margin degradation, nor has it proven that customers will remain loyal if a competitor builds similar capacity or if conventional ingredient prices fall.

The manufacturing moat question

In theory, fermentation-derived ingredients offer Bolt Projects a moat: proprietary microbes, fermentation know-how, and intellectual property that competitors cannot easily replicate. In practice, the moat is uncertain. Fermentation science is well-understood, and any well-capitalized competitor with access to skilled scientists and capital for manufacturing can attempt to copy the approach. The real moat, if one exists, would be operational: the ability to manufacture more efficiently than competitors, to maintain quality at scale, and to lock in long-term supply agreements with major brands. Those advantages are fragile and require continuous execution.

For investors, Bolt Projects represents a bet on the emergence of fermentation-derived ingredients as a material share of the beauty and textile markets. If that shift happens and Bolt Projects can capture significant share, the company could become a valuable industrial biotech player. If the shift happens more slowly than expected or if competitors emerge with comparable products at lower cost, the company’s value will be constrained by its capital intensity and limited profitability. The company’s public market performance will largely depend on execution on those manufacturing and commercial metrics.